BIOA
Price
$22.33
Change
+$0.86 (+4.01%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
992.19M
50 days until earnings call
Intraday BUY SELL Signals
COLL
Price
$34.60
Change
+$1.15 (+3.44%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
1.12B
37 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BIOA vs COLL

BIOA vs COLL Comparison Chart in %
View a ticker or compare two or three
VS
BIOA vs. COLL commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOA is a Hold and COLL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 24, 2026
Stock price -- (BIOA: $21.47 vs. COLL: $33.45)
Brand notoriety: BIOA and COLL are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BIOA: 107% vs. COLL: 114%
Market capitalization -- BIOA: $954.4M vs. COLL: $1.08B
BIOA [@Pharmaceuticals: Generic] is valued at $954.4M. COLL’s [@Pharmaceuticals: Generic] market capitalization is $1.08B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIOA’s FA Score shows that 1 FA rating(s) are green whileCOLL’s FA Score has 0 green FA rating(s).

  • BIOA’s FA Score: 1 green, 4 red.
  • COLL’s FA Score: 0 green, 5 red.
According to our system of comparison, BIOA is a better buy in the long-term than COLL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOA’s TA Score shows that 6 TA indicator(s) are bullish while COLL’s TA Score has 5 bullish TA indicator(s).

  • BIOA’s TA Score: 6 bullish, 4 bearish.
  • COLL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BIOA is a better buy in the short-term than COLL.

Price Growth

BIOA (@Pharmaceuticals: Generic) experienced а +8.22% price change this week, while COLL (@Pharmaceuticals: Generic) price change was -2.16% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.70%. For the same industry, the average monthly price growth was +0.08%, and the average quarterly price growth was +8.31%.

Reported Earning Dates

BIOA is expected to report earnings on Aug 12, 2026.

COLL is expected to report earnings on Jul 30, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.70% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COLL($1.12B) has a higher market cap than BIOA($992M). COLL has higher P/E ratio than BIOA: COLL (16.24) vs BIOA (1.37). BIOA YTD gains are higher at: 62.283 vs. COLL (-27.754). COLL has higher annual earnings (EBITDA): 411M vs. BIOA (-89.21M). COLL has more cash in the bank: 422M vs. BIOA (383M). BIOA has less debt than COLL: BIOA (4.03M) vs COLL (808M). COLL has higher revenues than BIOA: COLL (796M) vs BIOA (10.3M).
BIOACOLLBIOA / COLL
Capitalization992M1.12B88%
EBITDA-89.21M411M-22%
Gain YTD62.283-27.754-224%
P/E Ratio1.3716.248%
Revenue10.3M796M1%
Total Cash383M422M91%
Total Debt4.03M808M0%
FUNDAMENTALS RATINGS
BIOA vs COLL: Fundamental Ratings
BIOA
COLL
OUTLOOK RATING
1..100
317
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
5771
SMR RATING
1..100
9835
PRICE GROWTH RATING
1..100
3561
P/E GROWTH RATING
1..100
783
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIOA's Valuation (40) in the Chemicals Specialty industry is in the same range as COLL (53) in the Pharmaceuticals Other industry. This means that BIOA’s stock grew similarly to COLL’s over the last 12 months.

BIOA's Profit vs Risk Rating (57) in the Chemicals Specialty industry is in the same range as COLL (71) in the Pharmaceuticals Other industry. This means that BIOA’s stock grew similarly to COLL’s over the last 12 months.

COLL's SMR Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for BIOA (98) in the Chemicals Specialty industry. This means that COLL’s stock grew somewhat faster than BIOA’s over the last 12 months.

BIOA's Price Growth Rating (35) in the Chemicals Specialty industry is in the same range as COLL (61) in the Pharmaceuticals Other industry. This means that BIOA’s stock grew similarly to COLL’s over the last 12 months.

BIOA's P/E Growth Rating (7) in the Chemicals Specialty industry is significantly better than the same rating for COLL (83) in the Pharmaceuticals Other industry. This means that BIOA’s stock grew significantly faster than COLL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOACOLL
RSI
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
68%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
65%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 14 days ago
70%
Declines
ODDS (%)
Bearish Trend 16 days ago
77%
Bearish Trend 2 days ago
67%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
72%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
BIOA
Daily Signal:
Gain/Loss:
COLL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCIVX14.08N/A
N/A
MFG Core Infrastructure Service
HQIYX21.82N/A
N/A
Hartford Equity Income Y
JCVCX19.46N/A
N/A
JHancock Classic Value C
VEMRX127.55N/A
N/A
Vanguard Emerging Mkts Stock Idx InsPlus
QRSIX53.38N/A
N/A
FPA Queens Road Small Cap Value Instl

BIOA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIOA has been loosely correlated with UPC. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BIOA jumps, then UPC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOA
1D Price
Change %
BIOA100%
+3.37%
UPC - BIOA
43%
Loosely correlated
-5.08%
AMLX - BIOA
27%
Poorly correlated
+3.89%
TKNO - BIOA
26%
Poorly correlated
-1.91%
COLL - BIOA
23%
Poorly correlated
-0.27%
HROW - BIOA
23%
Poorly correlated
-1.07%
More

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with AMRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
-0.27%
AMRX - COLL
42%
Loosely correlated
-0.62%
AMPH - COLL
42%
Loosely correlated
-2.60%
VTRS - COLL
37%
Loosely correlated
N/A
EBS - COLL
35%
Loosely correlated
-1.88%
ANIP - COLL
34%
Loosely correlated
+1.31%
More